172 related articles for article (PubMed ID: 19650371)
1. Autoimmune inflammatory myopathy after treatment with ipilimumab.
Hunter G; Voll C; Robinson CA
Can J Neurol Sci; 2009 Jul; 36(4):518-20. PubMed ID: 19650371
[No Abstract] [Full Text] [Related]
2. Case of the month. Autoimmune colitis secondary to CTLA-4 blockade.
Tsiaras A
JAAPA; 2011 Aug; 24(8):68. PubMed ID: 21850925
[No Abstract] [Full Text] [Related]
3. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.
Wilgenhof S; Neyns B
Ann Oncol; 2011 Apr; 22(4):991-993. PubMed ID: 21357649
[No Abstract] [Full Text] [Related]
4. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.
Dillard T; Yedinak CG; Alumkal J; Fleseriu M
Pituitary; 2010; 13(1):29-38. PubMed ID: 19639414
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab: controversies in its development, utility and autoimmune adverse events.
Weber J
Cancer Immunol Immunother; 2009 May; 58(5):823-30. PubMed ID: 19198837
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab.
Sondak VK; Smalley KS; Kudchadkar R; Grippon S; Kirkpatrick P
Nat Rev Drug Discov; 2011 Jun; 10(6):411-2. PubMed ID: 21629286
[No Abstract] [Full Text] [Related]
8. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
Weber J
Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab for advanced melanoma: let's not throw caution to the winds.
Lowe M; Delman KA
Oncology (Williston Park); 2010 Dec; 24(14):1296, 1299. PubMed ID: 21294473
[No Abstract] [Full Text] [Related]
10. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
11. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
12. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
Gordon IO; Wade T; Chin K; Dickstein J; Gajewski TF
Cancer Immunol Immunother; 2009 Aug; 58(8):1351-3. PubMed ID: 19052742
[No Abstract] [Full Text] [Related]
13. Treating cancer by targeting the immune system.
Hwu P
N Engl J Med; 2010 Aug; 363(8):779-81. PubMed ID: 20818880
[No Abstract] [Full Text] [Related]
14. Ipilimumab: a promising immunotherapy for melanoma.
Thumar JR; Kluger HM
Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT imaging of an anti-CTLA-4 antibody-associated autoimmune pancolitis.
Goethals L; Wilgenhof S; De Geeter F; Everaert H; Neyns B
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1390-1. PubMed ID: 21365253
[No Abstract] [Full Text] [Related]
17. Ipilimumab for advanced melanoma: a nursing perspective.
Ledezma B
Oncol Nurs Forum; 2009 Jan; 36(1):97-104. PubMed ID: 19136343
[TBL] [Abstract][Full Text] [Related]
18. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
Kaehler KC; Egberts F; Lorigan P; Hauschild A
Melanoma Res; 2009 Oct; 19(5):333-4. PubMed ID: 19512947
[TBL] [Abstract][Full Text] [Related]
19. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
20. CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma.
Tarhini AA; Kirkwood JM
Oncology (Williston Park); 2010 Dec; 24(14):1302, 1304. PubMed ID: 21294474
[No Abstract] [Full Text] [Related]
[Next] [New Search]
